Sarepta Therapeutics, Inc.
https://www.sarepta.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Sarepta Therapeutics, Inc.
As COVID-19 Vaccine Sales Surge, BioNTech Pledges 40% Will Go To Poorer Nations
Angela Merkel consulted company’s CEO before opposing IP waiver, backing the future of Germany’s new ‘big biotech’ company.
COVID-19 Vaccine Regulatory Strategy Evolving With The Pandemic
AstraZeneca and Novavax have not filed EUAs for their vaccines, and they never might. The pathway remains viable in the short-term, but as BLAs are approved and supplies are no longer short, the window may close.
Pfizer/BioNTech’s COVID-19 Vaccine Moves Into Adolescents; Adcomm To Weigh Broader Pediatric Issues
Emergency use authorization in 12-15 year-olds follows announcement of a June advisory committee meeting on pediatric data requirements, including the FDA’s criteria for younger children. Authorization for US adolescents has raised ethical questions about prioritizing this lower-risk group over hard-hit populations overseas.
Deal Watch: AZ, Alchemab To Study Immune Response For Novel Cancer Targets
Also, deals involving AbCellera/Angios, AstraZeneca/Alchemab, Kowa/Esteve, OSE/Veloxis, Tris/Park, Core One/Akome and Vertex/Obsidian.
Company Information
- Industry
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Antisense, Oligonucleotides
- Gene Therapy, Cell Therapy
- Large Molecule
- Other Names / Subsidiaries
-
- AVI BioPharma, Inc.
- Ercole Biotech, Inc.
- Myonexus Therapeutics, Inc.